Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB

Core Insights - Castle Biosciences announced new data on the DecisionDx-Melanoma's i31-SLNB test for predicting sentinel lymph node (SLN) positivity, to be presented at the SSO 2026 Annual Meeting [1][2] Group 1: Test Performance and Validation - Initial reports from a prospective, multicenter study confirmed that DecisionDx-Melanoma impacts SLNB decision-making and identifies low-risk patients for nodal metastasis [2] - The i31-SLNB algorithm integrates a 31-gene expression profile score with clinicopathologic factors, providing a more precise risk estimation than traditional staging criteria [3] - DecisionDx-Melanoma has been clinically validated in over 10,000 patient samples and has been ordered more than 220,000 times since its launch, showing an association with improved patient survival [6] Group 2: Clinical Application and Guidelines - The test enhances risk stratification for patients with stage I–III cutaneous melanoma, offering personalized risk assessments for SLN positivity and recurrence/metastasis [5] - The data supports risk-aligned management decisions consistent with National Comprehensive Cancer Network® guidelines, including considerations for SLNB [2][5] Group 3: Company Overview - Castle Biosciences focuses on developing innovative diagnostic tests to improve health outcomes, particularly in dermatologic and gastroenterological diseases [7] - The company emphasizes a patient-first approach, empowering patients and clinicians through advanced molecular tests [8]